Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gaucher's Disease - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Gaucher's Disease - Pipeline Review, H1 2015', provides an overview of the Gaucher's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Gaucher's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gaucher's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gaucher's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Gaucher's Disease Overview 9 Therapeutics Development 10 Pipeline Products for Gaucher's Disease - Overview 10 Pipeline Products for Gaucher's Disease - Comparative Analysis 11 Gaucher's Disease - Therapeutics under Development by Companies 12 Gaucher's Disease - Therapeutics under Investigation by Universities/Institutes 15 Gaucher's Disease - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Gaucher's Disease - Products under Development by Companies 19 Gaucher's Disease - Products under Investigation by Universities/Institutes 21 Gaucher's Disease - Companies Involved in Therapeutics Development 22 Amicus Therapeutics, Inc. 22 Bioorganic Research and Services S.A. 23 Biosidus S.A. 24 Dong-A Socio Group 25 Genzyme Corporation 26 greenovation Biotech GmbH 27 ISU ABXIS Co.,Ltd. 28 JCR Pharmaceuticals Co., Ltd. 29 Lixte Biotechnology Holdings, Inc. 30 Neuraltus Pharmaceuticals, Inc. 31 Pharming Group N.V. 32 Protalix BioTherapeutics, Inc. 33 ReGenX Biosciences, LLC 34 The International Biotechnology Center (IBC) "Generium" 35 UAB Profarma 36 Gaucher's Disease - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 afegostat tartrate + ERT - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ambroxol - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 BNT-001 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 eliglustat tartrate - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Gene therapy to Activate Glucocerebrosidase for Gaucher's Disease - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Gluco-Cerebosidase - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 imiglucerase biosimilar - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 imiglucerase biosimilar - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 imiglucerase biosimilar - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 imiglucerase biosimilar - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 imiglucerase biosimilar - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 JR-101 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 LB-201 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LB-205 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NP-003 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PRX-112 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Recombinant Enzyme for Gaucher's Disease - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Gaucher's Disease - Recent Pipeline Updates 71 Gaucher's Disease - Dormant Projects 75 Gaucher's Disease - Discontinued Products 76 Gaucher's Disease - Product Development Milestones 77 Featured News & Press Releases 77 Nov 21, 2014: Cerdelga recommended for approval in type 1 Gaucher disease 77 Sep 02, 2014: Shire's VPRIV400 units/vial launched in Japan for the improvement of symptoms of Gaucher disease 77 Aug 19, 2014: FDA approves new drug to treat a form of Gaucher disease 78 Jul 04, 2014: Shire's VPRIV approved in Japan for the improvement of symptoms of Gaucher disease 79 Jun 18, 2014: Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease 80 Mar 14, 2014: Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots, of VPRIV (velaglucerase alfa for injection) 80 Feb 14, 2014: Shire Announces FDA Approval of Manufacturing Facility for VPRIV (Velaglucerase Alfa for Injection) Drug Substance 81 Feb 12, 2014: Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014 82 Dec 11, 2013: FDA Grants Priority Review for Genzyme's Cerdelga, an Investigational Oral Therapy for Gaucher Disease 83 Dec 11, 2013: FDA Grants Priority Review for Genzyme's Cerdelga, an Investigational Oral Therapy for Gaucher Disease 83 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 86 Disclaimer 86
List of Tables Number of Products under Development for Gaucher's Disease, H1 2015 10 Number of Products under Development for Gaucher's Disease - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Late Stage Development, H1 2015 16 Comparative Analysis by Clinical Stage Development, H1 2015 17 Comparative Analysis by Early Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Gaucher's Disease - Pipeline by Amicus Therapeutics, Inc., H1 2015 22 Gaucher's Disease - Pipeline by Bioorganic Research and Services S.A., H1 2015 23 Gaucher's Disease - Pipeline by Biosidus S.A., H1 2015 24 Gaucher's Disease - Pipeline by Dong-A Socio Group, H1 2015 25 Gaucher's Disease - Pipeline by Genzyme Corporation, H1 2015 26 Gaucher's Disease - Pipeline by greenovation Biotech GmbH, H1 2015 27 Gaucher's Disease - Pipeline by ISU ABXIS Co.,Ltd., H1 2015 28 Gaucher's Disease - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2015 29 Gaucher's Disease - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 30 Gaucher's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2015 31 Gaucher's Disease - Pipeline by Pharming Group N.V., H1 2015 32 Gaucher's Disease - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 33 Gaucher's Disease - Pipeline by ReGenX Biosciences, LLC, H1 2015 34 Gaucher's Disease - Pipeline by The International Biotechnology Center (IBC) "Generium", H1 2015 35 Gaucher's Disease - Pipeline by UAB Profarma, H1 2015 36 Assessment by Monotherapy Products, H1 2015 37 Assessment by Combination Products, H1 2015 38 Number of Products by Stage and Target, H1 2015 40 Number of Products by Stage and Mechanism of Action, H1 2015 42 Number of Products by Stage and Route of Administration, H1 2015 44 Number of Products by Stage and Molecule Type, H1 2015 46 Gaucher's Disease Therapeutics - Recent Pipeline Updates, H1 2015 71 Gaucher's Disease - Dormant Projects, H1 2015 75 Gaucher's Disease - Discontinued Products, H1 2015 76
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
